Business Wire

EVÄVAARA-DESIGN

11.5.2021 12:48:07 CEST | Business Wire | Press release

Share
Evävaara Design Takes up Remote Working Challenges With a New Kind of Home Office

Remote working has raised a number of challenges that have been taken up by Finnish pioneering designer of functional furniture, Evävaara Design. Evävaara is launching two completely new workstation designs to fit any home: the larger, mobile sshhh 3 and the smaller sshhh 7 . The workstations support the wellbeing of employees with good ergonomic and acoustic design.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005612/en/

Antti Evävaara, founder and chief designer of Evävaara Design, has almost twenty years’ experience in designing and producing functional furniture, with solid expertise in good acoustics and user comfort, which provide the basis for their workstation design.

“In today’s world we are constantly surrounded by irritants and noise that can make it hard to focus on something. Our products aim to create a quiet, personal space that allows you to focus”, says Evävaara .

The furniture-shaped workstations designed by Evävaara are a response to the challenges posed by the increase in remote working. According to remote work and virtual leadership expert Ulla Vikman of Timanttia Consulting, those who do a great deal of remote work, often experience interruptions and are sometimes challenged by a blurred line between work and free time.

“Someone who does a great deal of remote work would be distracted if the necessary tools, such as displays and paperwork, are constantly on all over their home. By intruding your thoughts constantly, these things tend to increase stress levels and focusing becomes more difficult”, says Vikman .

The design of Evävaara workstations is focused on a number of details that support concentration and ergonomics. The wood and felt of the workstation muffles both external and internal noise and improves the acoustics of the whole room. Standard equipment for the workstation includes

  • Power sockets and cords
  • USB port
  • LED lights
  • Storage pockets for paperwork and other materials

The larger sshhh3 can be purchased with an additional, adjustable chair. After work, the workstation doors are simply closed and the workstation becomes a mobile cabinet. A neutral colour scheme makes the unit blend seamlessly in any home environment.

In order to boost the efficiency of your working day, Evävaara Design workstations are easy to deploy. The workstation is delivered assembled and ready to use. Evävaara Design workstations are available direct from the designer.

Today the products of Evävaara Design are in use all over Europe wherever a calm space is required, for instance in open plan offices and libraries. They have also garnered some international interest since Vincent Gregoire, Nelly Rodi’s creative director and a celebrity in the business, included Evävaara products in a video showcasing new trends at the Maison & Objet fair in February.

More information: https://www.evavaaradesign.com/etatyopisteet/

Evavaara Design is a Finnish pioneer in functional furniture design in Europe – creating quiet corners for every environment.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye